[HTML][HTML] Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic …

…, V Bucumi, B Kebede, MS Yibi, A Meité… - PLoS neglected …, 2018 - journals.plos.org
Background Intervention guidelines against Schistosoma mansoni are based on the Kato-Katz
technique. However, Kato-Katz thick smears show low sensitivity, especially for light-…

[HTML][HTML] Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection in …

…, CH Campbell Jr, EK N'Goran, A Meite… - The American journal …, 2020 - ncbi.nlm.nih.gov
This report summarizes the design and outcomes of randomized controlled operational
research trials performed by the Bill & Melinda Gates Foundation–funded Schistosomiasis …

[HTML][HTML] Prevalence and risk factors for schistosomiasis among schoolchildren in two settings of Côte d'Ivoire

EK Angora, J Boissier, H Menan, O Rey, K Tuo… - Tropical medicine and …, 2019 - mdpi.com
Schistosomiasis is a parasitic disease affecting more than 250 million people, primarily in
sub-Saharan Africa. In Côte d’Ivoire both Schistosoma haematobium (causing urogenital …

Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Cote d'Ivoire: an open-label randomized …

CM Bjerum, AF Ouattara, M Aboulaye… - Clinical Infectious …, 2020 - academic.oup.com
Background Improved drug regimens are needed to accelerate elimination of lymphatic
filariasis in Africa. This study determined whether a single co-administered dose of ivermectin …

[HTML][HTML] Molecular characterization and distribution of Schistosoma cercariae collected from naturally infected bulinid snails in northern and central Côte d'Ivoire

YNT Tian-Bi, B Webster, CK Konan, F Allan… - Parasites & vectors, 2019 - Springer
Background Accurate identification of schistosome species infecting intermediate host
snails is important for understanding parasite transmission, schistosomiasis control and …

[HTML][HTML] Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without …

C Edi, CM Bjerum, AF Ouattara… - PLoS neglected …, 2019 - journals.plos.org
Background A single co-administered dose of ivermectin (IVM) plus diethylcarbamazine (DEC)
plus albendazole (ALB), or triple-drug therapy, was recently found to be more effective for …

[HTML][HTML] Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes

MM Lloyd, R Gilbert, NT Taha, GJ Weil, A Meite… - Acta tropica, 2015 - Elsevier
Commonly used methods for diagnosing Onchocerca volvulus infections (microscopic
detection of microfilariae in skin snips and nodule palpation) are insensitive. Improved methods …

[HTML][HTML] Sustaining control of schistosomiasis mansoni in western Côte d'Ivoire: results from a SCORE study, one year after initial praziquantel administration

RK Assaré, YNT Tian-Bi, PK Yao… - PLoS neglected …, 2016 - journals.plos.org
Background The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE)
has launched several large-scale trials to determine the best strategies for gaining and …

[HTML][HTML] Lessons learned in conducting mass drug administration for schistosomiasis control and measuring coverage in an operational research setting

…, MN Clements, EK N'Goran, A Meite… - The American journal …, 2020 - ncbi.nlm.nih.gov
The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was
created to conduct research that could inform programmatic decision-making related to …

Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?

…, NK Biritwum, R Bougma, M Aboulaye… - The Lancet infectious …, 2018 - thelancet.com
Lymphatic filariasis in Africa is caused by the parasite Wuchereria bancrofti and remains a
major cause of morbidity and disability in 74 countries globally. A key strategy of the Global …